Source-grounded facts extracted from Bio Green Med Solution, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Bio Green Med Solution, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2025-06-18 meeting.
“Approval by an Advisory Vote the Executive Compensation. Our shareholders approved, by an advisory vote, the compensation of our named executive officers and directors, as disclosed in this proxy statement.”
Bio Green Med Solution, Inc. shareholders approved Approval of the Appointment of Auditors at the 2025-06-18 meeting.
“Our shareholders ratified the appointment of SFAI Malaysia Plt. (PCAOB: 7167), as our independent auditors for the 2026 fiscal year ending December 31, 2026.”
Bio Green Med Solution, Inc. shareholders approved Election of Class I Directors at the 2025-06-18 meeting.
“Election of Directors : Our shareholders voted to elect the following individuals as Class I Directors, each of whom has been approved for re-election for a three-year term expiring at the 2029 annual meeting of stockholders: (a) Dr. Satis Waran Nair Krishnan, and (b) Inigo Angel Laurduraj.”
Bio Green Med Solution, Inc. issued 1,103,338 shares of Common Stock of common stock to foreign accredited investors for $0.72 per share for aggregate gross proceeds of $794,403.
“an aggregate of 1,103,338 shares of Common Stock, par value $0.001 (the “Shares”) of the Company at a purchase price of $0.72 per share for aggregate gross proceeds of $794,403”
Bio Green Med Solution, Inc. entered into Purchase Agreement with certain foreign accredited investors valued at aggregate gross proceeds of $794,403 (effective 2025-06-10).
“On June 10, 2025, Bio Green Med Solution, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain foreign accredited investors (the “Investors”), pursuant to which the Investors agreed to purchase from the Company an aggregate of 1,103,338 shares of Common Stock, par value $0.001 (the “Shares”) of the Company at a purchase price of $0.72 per share for aggregate gross proceeds of $794,403, subject to the terms and conditions of the Purchase Agreement.”
Bio Green Med Solution, Inc. entered into Business Combination Agreement with Future NRG Sdn. Bhd. and each of the shareholders of FNRG valued at The Selling Shareholders will voluntarily exchange all of their ordinary shares in FNRG for shares o (effective 2026-06-04).
“On June 4, 2026, Bio Green Med Solution, Inc., a Delaware corporation (the "Company"), Future NRG Sdn. Bhd., a Malaysia private limited company ("FNRG") and each of the shareholders of FNRG (the "Selling Shareholders"), entered into a Business Combination Agreement (the "BCA"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the BCA, the Selling Shareholders will voluntarily exchange all of their ordinary shares in FNRG for shares of common stock, par value $0.001 of the Company (the "Exchange Shares"), resulting in FNRG becoming a wholly owned subsidiary of the Company (the "Exchange").”
Bio Green Med Solution, Inc. reported first quarter ended March 31, 2026 results: revenue $0.8 million, net income Net loss for the three months ended March 31, 2026, was $0.2 million.
“have successfully transitioned our operations to focus on fire safety protection and distribution, and we are encouraged by the early momentum in this business, which generated $0.8 million in product revenue during the quarter.” “Our team has also made significant strides in strengthening our cost structure. General and administrative expenses declined by”
Bio Green Med Solution, Inc. reported fourth quarter and year ended December 31, 2025 results: net income Net loss for the three months and year ended December 31, 2025, was $0.6 million and $3.0 million.
“announcing certain financial results for the fourth quarter and year ended December 31, 2025”
Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5810(c)(3)(D)).
“um Market Value of Publicly Held Shares (as such terms are defined under the Nasdaq Listing Rules, “MVPHS”) of $1 million. The Staff’s letter further advised that for the prior 30 consecutive business days, the Preferred Stock no longer meets this requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has 180 calendar days, or until March 10, 2026, to regain compliance with the MVPHS requirement for its Preferred Stock. On March 12, 2026, the Company received another letter from the Staff of Nasdaq, notifying the Company that (i) the Preferred Stock has not regained com”
Bio Green Med Solution, Inc. issued an aggregate of 1,402,605 shares of Common Stock of common stock to certain accredited investors (the "Holders").
“The shares of Common Stock issuable to the Holders pursuant to the Exchange Agreement will be issued without registration under the Securities Act of 1933, as amended, in reliance on the exemption provided by Section 3(a)(9).”
Bio Green Med Solution, Inc. completed a disposition involving Tethra Biosciences Inc. for $300,000, plus a further potential Milestone of $170,000 (closed 2025-10-06).
“of the Company related to Plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies (“Plogo”), for a purchase price of $300,000, plus a further potential Milestone (as defined in the Purchase Agreement) of $170,000. The Purchase Agreement contains customary representations, warranties and covenants. The”
Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5460(a)(2), 5810(c)(3)(D)).
“September 11, 2025, Bio Green Med Solution, Inc. ( fka Cyclacel Pharmaceuticals, Inc.) received a letter from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that its 6% Convertible Exchangeable Preferred Stock (listed on the Nasdaq Capital Market under the symbol “BGMSP”) (the “Preferred Stock”) no longer complies with the requirement under Nasdaq Listing Rule 5460(a)(2) to maintain a minimum Market Value of Publicly Held Shares (as such terms are defined under the Nasdaq Listing Rules, “MVPHS”) of $1 million. The Staff’s”
Bio Green Med Solution, Inc. completed an acquisition involving FITTERS Diversified Berhad for 699,158 shares of common stock, par value $0.001, of the Company (closed 2025-09-12).
“f FITTERS Diversified Berhad, a Malaysian publicly listed company (“Fitters Parent”), pursuant to a share exchange agreement”
Bio Green Med Solution, Inc. engaged SFAI Malaysia PLT as its auditor.
“On August 22, 2025, the Audit Committee approved the engagement of SFAI as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, effective August 23, 2025.”
Bio Green Med Solution, Inc. dismissed Bush & Associates CPA LLP as its auditor.
“ismissal of Independent Registered Public Accounting Firm On August 22, 2025, the Audit Committee of the Board of Directors (the “Audit Committee”) of Cyclacel Pharmaceuticals, Inc. (the “Company”) approved the dismissal of Bush & Associates CPA LLP (“Bush”), as the Company’s independent registered public accounting firm, effective immediately.”
Bio Green Med Solution, Inc.: Filing of Amended and Restated Certificate of Designations for Series F Convertible Preferred Stock removing the Series F Ownership Limitation (effective 2025-07-28).
“On July 28, 2025, after obtaining the approval of the Board of Directors and majority stockholder of Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the “Company”) as disclosed in the Company’s Definitive Information Statement on Schedule 14C filed with the Securities and Exchange Commission on July 7, 2025 (the “Schedule 14C”), the Company filed an Amended and Restated Certificate of Designations, Preferences, Rights and Limitations of Series F Convertible Preferred Stock (the “Restated Certificate of Designation”) with the Secretary of State of the State of Delaware.”
Bio Green Med Solution, Inc.: Filed Certificate of Amendment to implement a one-for-fifteen reverse stock split to meet Nasdaq bid price requirements (effective 2025-07-07).
“On July 2, 2025, Cyclacel Pharmaceuticals, Inc. (the “Company”) filed an amendment to its Certificate of Incorporation (“Certificate of Amendment”) to implement a one-for-fifteen reverse stock split.”
Bio Green Med Solution, Inc.: One-for-sixteen reverse stock split amendment to Certificate of Incorporation (effective 2025-05-12).
“On May 7, 2025, Cyclacel Pharmaceuticals, Inc. (the “Company”) filed an amendment to its Certificate of Incorporation (“Certificate of Amendment”) to implement a one-for-sixteen reverse stock split.”
Bio Green Med Solution, Inc.: Removed the Series E Ownership Limitation on conversion and voting of Series E Convertible Preferred Stock (effective 2025-04-25).
“The Restated Certificate of Designation removes such Series E Ownership Limitation so that the shares of Series E Convertible Preferred Stock may be converted and voted without regard to such Series E Ownership Limitation.”
Bio Green Med Solution, Inc.: Increased authorized common stock from 250,000,000 to 600,000,000 shares (effective 2025-04-25).
“The Certificate of Amendment increased the number of authorized shares of the Company’s common stock from two hundred fifty million (250,000,000) to six hundred million (600,000,000).”
Satis Waran Nair Krishnan was appointed as independent director at Bio Green Med Solution, Inc..
“On April 2, 2025, coinciding with the effective time of the resignation of Messers. Ben-Tzvi and Natan, as independent directors, the Company appointed Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, as independent directors, on the Company’s board of directors (the “Board”) to fill the vacancies and to hold office until their successor shall have been duly elected and qualified or until her or his earlier death, resignation or removal.”
Inigo Angel Laurduraj was appointed as independent director at Bio Green Med Solution, Inc..
“On April 2, 2025, coinciding with the effective time of the resignation of Messers. Ben-Tzvi and Natan, as independent directors, the Company appointed Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, as independent directors, on the Company’s board of directors (the “Board”) to fill the vacancies and to hold office until their successor shall have been duly elected and qualified or until her or his earlier death, resignation or removal.”
David Natan resigned as independent director at Bio Green Med Solution, Inc..
“on March 31, 2025, each of Avraham Ben-Tzvi and David Natan agreed to delay their previously announced resignation of their services to the Company as independent director from March 31, 2025 until the filing date of the Form 10-K. On such filing date, each of their resignation shall be automatically effective.”
Avraham Ben-Tzvi resigned as independent director at Bio Green Med Solution, Inc..
“on March 31, 2025, each of Avraham Ben-Tzvi and David Natan agreed to delay their previously announced resignation of their services to the Company as independent director from March 31, 2025 until the filing date of the Form 10-K. On such filing date, each of their resignation shall be automatically effective.”
David Lazar resigned as co-principal financial officer and co-principal accounting officer at Bio Green Med Solution, Inc..
“On March 31, 2025, David Lazar, the Company’s co-principal financial officer and co-principal accounting officer agreed to delay his previously announced resignation from March 31, 2025 until the date that the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”), is filed with the Securities and Exchange Commission (“SEC”). On such date, Mr. Lazar’s resignation shall be automatically effective.”
Bio Green Med Solution, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).
“February 25, 2025, the Nasdaq Stock Market notified the Company that it has regained compliance with the equity requirement in Listing Rule 5550(b)(1) (the “Equity Rule”), as required by the Nasdaq Hearing Panel’s decision dated October 22, 2024. As previously reported by the Company on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on October 24, 2024, on October 15, 2024, the Company met with the Nasdaq Hearings Panel regarding the Company’s potential delisting from The Nasdaq Stock Market as a result of its non-compliance with the Equity Rule. On October 22, 2024, t”
Bio Green Med Solution, Inc. underwent a change of control involving Datuk Dr. Doris Wong Sing Ee for $6,300,000 (closed 2025-02-26).
“that certain securities purchase agreement between the Seller and the Company dated January 2, 2025. In consideration for the sale of the Securities, the Investor delivered $6,300,000 (the “Purchase Price”) less the holdback amount of $100,000 (the “Holdback Amount”) to the escrow agent. The Purchase Price included a cash brokerage fee in the amount of $800,000”
Datuk Dr. Doris Wong Sing Ee was elected as Director at Bio Green Med Solution, Inc..
“Datuk Dr. Doris Wong Sing Ee was also elected to the Board of the Company as of the effective date.”
Datuk Dr. Doris Wong Sing Ee was appointed as Chief Executive Officer at Bio Green Med Solution, Inc..
“the Board appointed Datuk Dr. Doris Wong Sing Ee, as Chief Executive Officer and, in such role, she will serve as the Company’s principal executive officer.”
David Lazar resigned as Interim Chief Executive Officer at Bio Green Med Solution, Inc..
“David Lazar, the Company’s interim Chief Executive Officer, interim principal financial officer, interim principal accounting officer, and Secretary, provided notice of his resignation as Chief Executive Officer and Secretary of the Company effective February 26, 2025.”
Bio Green Med Solution, Inc.: Removed Series D Ownership Limitation from Series D Convertible Preferred Stock Certificate of Designation (effective 2025-02-06).
“The Series D Amendment removes such Series D Ownership Limitation so that the shares of Series D Convertible Preferred Stock may be converted and voted without regard to such Series D Ownership Limitation.”
Bio Green Med Solution, Inc.: Removed Series C Ownership Limitation from Series C Convertible Preferred Stock Certificate of Designation (effective 2025-02-10).
“The Series C Amendment removes such Series C Ownership Limitation so that the shares of Series C Convertible Preferred Stock may be converted and voted without regard to such Series C Ownership Limitation.”
Bio Green Med Solution, Inc.: Increased authorized common shares from 100,000,000 to 250,000,000 (effective 2025-02-10).
“The Charter Amendment was filed with the Secretary of State of the State of Delaware on February 10, 2025 and became effective on such date.”
Avraham Ben-Tzvi was appointed as Director at Bio Green Med Solution, Inc..
“The Board of Directors also appointed Messrs. David Natan and Avraham Ben-Tzvi as members of the Board of Directors, effective as of the signing of the Purchase Agreement and as of January 5, 2025, respectively.”
David Natan was appointed as Director at Bio Green Med Solution, Inc..
“The Board of Directors also appointed Messrs. David Natan and Avraham Ben-Tzvi as members of the Board of Directors, effective as of the signing of the Purchase Agreement and as of January 5, 2025, respectively.”
Karin Walker resigned as Director at Bio Green Med Solution, Inc..
“Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the "Resigning Directors") resigned effective as of the signing of the Purchase Agreement.”
Kenneth Ferguson resigned as Director at Bio Green Med Solution, Inc..
“Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the "Resigning Directors") resigned effective as of the signing of the Purchase Agreement.”
Brian Schwartz resigned as Director at Bio Green Med Solution, Inc..
“Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the "Resigning Directors") resigned effective as of the signing of the Purchase Agreement.”
Christopher Henney resigned as Director at Bio Green Med Solution, Inc..
“Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the "Resigning Directors") resigned effective as of the signing of the Purchase Agreement.”
Robert Spiegel resigned as Director at Bio Green Med Solution, Inc..
“Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the "Resigning Directors") resigned effective as of the signing of the Purchase Agreement.”
David E. Lazar was appointed as interim Chief Executive Officer at Bio Green Med Solution, Inc..
“the Board of Directors appointed Mr. Lazar as interim Chief Executive Officer of the Company, effective as of the signing of the Purchase Agreement.”
Spiro Rombotis resigned as Chief Executive Officer at Bio Green Med Solution, Inc..
“Mr. Spiro Rombotis resigned as Chief Executive Officer of the Company”
Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“December 6, 2024, Cyclacel Pharmaceuticals, Inc. (the “Company”) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share, (the “Common Stock”) for the last 30 consecutive business days, the Common Stock did not meet the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5550(a)(2), initiating an automatic 180 calendar-day grace period for the Company to regain compliance. The notice has no immediate effect on the listing or trading of the Compan”
Bio Green Med Solution, Inc. engaged Bush & Associates CPA LLP as its auditor.
“On November 5, 2024, the Audit Committee approved the engagement of Bush as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, effective immediately.”
Bio Green Med Solution, Inc. dismissed Crowe LLP as its auditor.
“hange in Registrant ’ s Certifying Accountants (a) Dismissal of Independent Registered Public Accounting Firm On November 5, 2024, the Audit Committee of the Board of Directors (the “Audit Committee”) of Cyclacel Pharmaceuticals, Inc. (the “Company”) approved the dismissal of Crowe LLP, (“Crowe”) as the Company’s independent registered public accounting firm, effective”
Dr. Christopher Henney changed role as Director at Bio Green Med Solution, Inc..
“Effective June 21, 2024, by resolution of the board of directors of the Company, Dr. Samuel L. Barker was appointed Chair of the board of directors to replace Dr. Christopher Henney, who requested to step down as Chair but will continue as a director of the Company.”
Dr. Samuel L. Barker was appointed as Chair of the board at Bio Green Med Solution, Inc..
“Effective June 21, 2024, by resolution of the board of directors of the Company, Dr. Samuel L. Barker was appointed Chair of the board of directors to replace Dr. Christopher Henney, who requested to step down as Chair but will continue as a director of the Company.”
Bio Green Med Solution, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the three months March 31, 2024, was $2.9 million (including stock-based compensation expense of $0.2 milli.
“Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today first quarter financial results and provided a business update.”
Bio Green Med Solution, Inc. entered into Purchase Agreement with an institutional investor valued at approximately $8.0 million (effective 2024-04-30).
“On April 30, 2024, Cyclacel Pharmaceuticals, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Purchaser ”) for the issuance and sale in a private placement (the “ Private Placement ”) of (i) 145,000 shares of the Company’s common stock”
Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“March 27, 2024, Cyclacel Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) because the Company reported stockholders’ equity of less than $2.5 million as of December 31, 2023. The Company’s stockholders’ equity was $607,000 as of December 31, 2023. The Company must submit a plan to the Staff no later than May 10, 2024 advising of actions it has taken or will take to regain compliance with Nasdaq Listing”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.